Merck: OTL-06 should further validate SAC-TMT but numerous 2H events to define lung

研报英文原文证据摘录

Merck: OTL-06 should further validate SAC-TMT but numerous 2H events to define lung

population, at the risk of possibly excluding Datroway from part of the 1L NSQ NSCLC

market.

Is SAC-TMT combinable with chemotherapy?

SAC-TMT is evaluated either as monotherapy or in combo with a biologic, mostly

Keytruda but sometimes Avastin where Avastin is standard of care. The most likely

explanation for why SAC-TMT isn’t combined with conventional cytotoxics is that

overlapping myelosuppression would be dose-limiting and compromise delivery of the

combo regimen. Specific development choices appear guided by this, such as multiple

trials of SAC-TMT as maintenance to insert SAC-TMT into treatment without having to

combine. If true and inescapable, it could become a constraint on SAC-TMT

development. Chemotherapy combinations are the foundation of first-line therapy in

several solid tumors (importantly NSCLC). As such, SAC-TMT must be highly active if it

were to replace standard chemotherapy in those settings. Kelun is conducting a Ph2

NSCLC expansion trial evaluating combination of SAC-TMT (two doses) plus

Keytruda/carboplatin in 1L NSCLC to directly address combinability. Readout is expected

2H 2026

2H26 offers several readouts that could shape lung

Metastatic NSCLC is a large market, thus a high priority tumor setting for novel pipeline

assets. So far, SAC-TMT development efforts have been focused on select lung cancer

segments like EGFR-mutant, 1L squamous (SQ) and 1L PD-L1 ≥ 50%. In the context of

the Keytruda loss-of-exclusivity (LOE), non-AGA lung makes up an estimated $11bn of

consensus forecasts. Ongoing SAC-TMT pivotal trials cover up to 55% of the 1L non-

AGA US patient opportunity, leaving the other 45% in play (1L NSQ treated with

Keytruda/chemotherapy; KN-189).